WATERTOWN, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development
of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the
Company's Chief Scientific Officer and SVP, is scheduled to participate
in the 2014 AsiaTIDES Conference being held in Tokyo, Japan February
25-27, 2014. Dr. Brown will chair the main conference plenary session of
keynote presentations addressing drug delivery systems for peptides and
oligonucleotides; give a presentation titled, "Physical and Chemical
Characterization of LNP Formulations of Oligonucleotides vs. Biological
Activities;" and participate as a panel member discussing delivery
approaches and challenges on Thursday, February 27, 2014.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined.
Dicerna is using its proprietary RNA interference (RNAi) technology
platform to build a broad pipeline in these therapeutic areas and
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners.
Dicerna Pharmaceuticals, Inc.
James B. Weissman,
Chief Business Officer
Chris Erdman, 781-235-3060
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media